Market Place
Sourcing Support
Minerva Neurosciences Reports Q3 2024 Financial Results & Update
05 Nov 2024 //
GLOBENEWSWIRE
Minerva Neurosciences Reports Q2 2024 Results And Business Updates
06 Aug 2024 //
GLOBENEWSWIRE
Minerva Neuro Q1 2024 Results, Business Update
01 May 2024 //
GLOBENEWSWIRE
Minerva`s schizophrenia drug rejected by FDA for 2nd time
28 Feb 2024 //
FIERCE BIOTECH
Minerva Reports Fourth Quarter and Fiscal Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Minerva Neurosciences Reports 2023 Third Quarter Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Minerva Reports 2023 Second Quarter Financial Results and Business Updates
01 Aug 2023 //
GLOBENEWSWIRE
Minerva Neurosciences Announces $20 Million in Private Placement
28 Jun 2023 //
GLOBENEWSWIRE
Minerva Neurosciences Reports 2023 First Quarter FYR and Business Updates
15 May 2023 //
GLOBENEWSWIRE
Minerva Neurosciences Announces Update on its NDAfor Roluperidone
10 May 2023 //
GLOBENEWSWIRE
Minerva Neurosciences to Report 1Q 2023 FYR & Business Updates on May 15, 2023
08 May 2023 //
GLOBENEWSWIRE
Minerva Neurosciences Announces the NDA Filing for Roluperidone
01 May 2023 //
GLOBENEWSWIRE
Minerva Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
Minerva Neurosciences to Report FY2022 Financial Results & Business Mar8, 2023
01 Mar 2023 //
GLOBENEWSWIRE
Minerva Neurosciences Reports 3Q 2022 Financial Results and Business Updates
09 Nov 2022 //
GLOBENEWSWIRE
Minerva Neurosciences to Report Third Quarter 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
FDA spurns Minerva’s schizophrenia drug in RTF
17 Oct 2022 //
ENDPTS
Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone
17 Oct 2022 //
GLOBENEWSWIRE
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
09 Sep 2022 //
GLOBENEWSWIRE
Minerva Neurosciences Inc (NASDAQ: NERV) Submits NDA for Roluperidone
02 Sep 2022 //
PRESS RELEASE
Minerva Submits New Drug Application to FDA for Roluperidone
22 Aug 2022 //
GLOBENEWSWIRE
Minerva Neurosciences Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Minerva Neurosciences Reports First Quarter 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
Minerva Updates on Type C Meeting; Prepares to submit NDA for Roluperidone
07 Apr 2022 //
GLOBENEWSWIRE
Minerva Neurosciences Reports Q4 2021 Financial Results and Business Updates
01 Mar 2022 //
GLOBENEWSWIRE
Minerva Publishes Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
28 Feb 2022 //
GLOBENEWSWIRE
FDA Recommends Type C Meeting for Minerva to Discuss Evidence for Roluperidone
03 Nov 2021 //
GLOBENEWSWIRE
Minerva Neurosciences to Report Third Quarter 2021 Financial Results
01 Nov 2021 //
GLOBENEWSWIRE
Minerva Neurosciences Appoints Dr. Ramana Kuchibhatla as Sr. VP and Head of R&D
08 Sep 2021 //
GLOBENEWSWIRE
Minerva 2nd Quarter 2021 Financial Results and Business Updates August 2, 2021
26 Jul 2021 //
GLOBENEWSWIRE
Minerva Soars on Positive Schizophrenia Drug Trial
12 May 2021 //
THESTREET
Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone
11 May 2021 //
GLOBENEWSWIRE
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and year Results
08 Mar 2021 //
GLOBENEWSWIRE
Minerva and Royalty Announce Sale of Seltorexant Royalty for up to $155M
19 Jan 2021 //
BIOSPACE
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA
01 Dec 2020 //
GLOBENEWSWIRE
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen
01 Jul 2020 //
GLOBENEWSWIRE
Minerva Neurosciences’ roluperidone fails in Phase III study
01 Jun 2020 //
CLINICALTRIALSARENA
Minerva Neurosciences’ roluperidone fails in Phase III study
01 Jun 2020 //
CLINICALTRIALSARENA
Minerva Announces Results Ph3 Trial of Roluperidone (MIN-101)
29 May 2020 //
GLOBENEWSWIRE
Minerva`s Announces Completion of Patient Enrollment Ph3 Trial of Roluperidone
05 Feb 2020 //
EINPRESSWIRE
